The relationship of antibodies to modified citrullinated vimentin and markers of bone and cartilage destruction in rheumatoid arthritis

International Journal of Rheumatology

Volumn 2014, Issue , 2014, Pages

  Avdeeva, A S ^a   Aleksandrova, E N ^a   Novikov, A A ^a   Smirnov, A V ^a   Cherkasova, M V ^a   Nasonov, E L ^a  

^a V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M RHEUMATOID FACTOR ANTIBODY; MODIFIED CITRULLINATED VIMENTIN; MODIFIED CITRULLINATED VIMENTIN ANTIBODY; STROMELYSIN; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BONE DESTRUCTION; BONE RADIOGRAPHY; CARTILAGE DEGENERATION; CLINICAL EVALUATION; CLINICAL INDICATOR; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS;

EID: 84899996920     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2014/464585     Document Type: Article

References (36)

1. Nasonov E. L., Karateev D. E., Balabanova R. M., Nasonov E. L., Nasonova V. A., Rheumatoid arthritis. Rheumatology: National Manual Moscow, Russia Geotar-Media 290 331. 2008 (Russian)
2. Novikov A. A., Aleksandrova E. N., Cherkasova M. V., Nasonov E. L., Current methods for laboratory diagnosis of rheumatoid arthritis Nauchno-Prakticheskaya Revmatologiya 2010 1 31 45
3. Nicaise-Roland P., Nogueira L., Demattei C., Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Annals of the Rheumatic Diseases 2013 72 3 357 362 10.1136/annrheumdis- 2011-201056
4. Song Y. W., Kang E. H., Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM 2009 103 3 139 146 2-s2.0-77950238310 10.1093/qjmed/hcp165
5. Klareskog L., Catrina A. I., Paget S., Rheumatoid arthritis. The Lancet 2009 373 9664 659 672 2-s2.0-60249090304 10.1016/S0140-6736(09)60008-8
6. Valesini G., Alessandri C., Anticitrullinated protein/peptide antibodies and rheumatoid factors: two distinct autoantibody systems. Arthritis Research and Therapy 2009 11 5, article 125 2-s2.0-75649133949 10.1186/ar2786
7. Turesson C., Jacobsson L. T. H., Sturfelt G., Matteson E. L., Mathsson L., Rönnelid J., Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 1 59 64 2-s2.0-33845968788 10.1136/ard.2006.054445
8. McInnes I. B., Schett G., Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology 2007 7 6 429 442 2-s2.0-34249720998 10.1038/nri2094
9. Lam J., Takeshita S., Barker J. E., Kanagawa O., Ross F. P., Teitelbaum S. L., TNF- α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. The Journal of Clinical Investigation 2000 106 12 1481 1488 2-s2.0-0034523328
10. Lubberts E., van den Bersselaar L., Oppers-Walgreen B., Schwarzenberger P., Coenen-De Roo C. J. J., Kolls J. K., Joosten L. A. B., van den Berg W. B., IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF- B ligand/osteoprotegerin balance1. Journal of Immunology 2003 170 5 2655 2662 2-s2.0-0037371262
11. Burrage P. S., Mix K. S., Brinckerhoff C. E., Matrix metalloproteinases: role in arthritis. Frontiers in Bioscience 2006 11 1 529 543 2-s2.0-32944465075 10.2741/1817
12. Bonassar L. J., Frank E. H., Murray J. C., Paguio C. G., Moore V. L., Lark M. W., Sandy J. D., Wu J.-J., Eyre D. R., Grodzinsky A. J., Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis and Rheumatism 1995 38 2 173 183 2-s2.0-0028843597 10.1002/art.1780380205
13. Unemori E. N., Bair M. J., Bauer E. A., Amento E. P., Stromelysin expression regulates collagenase activation in human fibroblasts: dissociable control of two metalloproteinases by interferon- γ The Journal of Biological Chemistry 1991 266 34 23477 23482 2-s2.0-0026335393
14. Gravallese E. M., Manning C., Tsay A., Synovial tissue in rheumatoid arthritis is asource of osteoclast differentiation factor. Arthritis and Rheumatism 2000 43 2 250 258
15. Stolina M., Adamu S., Ominsky M., Dwyer D., Asuncion F., Geng Z., Middleton S., Brown H., Pretorius J., Schett G., Bolon B., Feige U., Zack D., Kostenuik P. J., RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. Journal of Bone and Mineral Research 2005 20 10 1756 1765 2-s2.0-24644434101 10.1359/JBMR.050601
16. Harre U., Georgess D., Bang H., Bozec A., Axmann R., Ossipova E., Jakobsson P.-J., Baum W., Nimmerjahn F., Szarka E., Sarmay G., Krumbholz G., Neumann E., Toes R., Scherer H.-U., Catrina A. I., Klareskog L., Jurdic P., Schett G., Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. The Journal of Clinical Investigation 2012 122 5 1791 1802 2-s2.0-84860561645 10.1172/JCI60975
17. Harre U., Georgess D., Axmann R., Anti-citrullinated protein antibodies directly induce bone loss in rheumatoid arthritis. Annals of the Rheumatic Diseases 2012 71 supplement 3 59
18. Klareskog L., Lundberg K., Malmström V., Autoimmunity in rheumatoid arthritis: citrulline immunity and beyond. Advances in Immunology 2013 118 129 158 10.1016/B978-0-12-407708-9.00003-0
19. Månsson B., Geborek P., Saxne T., Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction. Annals of the Rheumatic Diseases 1997 56 2 91 96 2-s2.0-0030979067
20. Månsson B., Carey D., Alini M., Ionescu M., Rosenberg L. C., Poole A. R., Heinegard D., Saxne T., Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. The Journal of Clinical Investigation 1995 95 3 1071 1077 2-s2.0-0028934327
21. Skoumal M., Kolarz G., Klingler A., Serum levels of cartilage oligomeric matrix protein: a predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scandinavian Journal of Rheumatology 2003 32 3 156 161 2-s2.0-0038007034 10.1080/03009740310002498
22. Berglin E., Johansson T., Sundin U., Jidell E., Wadell G., Hallmans G., Rantapää-Dahlqvist S., Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Annals of the Rheumatic Diseases 2006 65 4 453 458 2-s2.0-33645116507 10.1136/ard.2005.041376
23. Forslind K., Ahlmén M., Eberhardt K., Hafström I., Svensson B., Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Annals of the Rheumatic Diseases 2004 63 9 1090 1095 2-s2.0-4344630375 10.1136/ard.2003.014233
24. Lindqvist E., Eberhardt K., Bendtzen K., Heinegård D., Saxne T., Prognostic laboratory markers of joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases 2005 64 2 196 201 2-s2.0-13244252643 10.1136/ard.2003.019992
25. Nieten M. M. J., van der Horst A. R., van Schaardenburg D., van der Horst-Bruinsma I. E., van de Stadt R. J., Aarden L., Dijkmans B. A. C., Hamann D., Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Annals of the Rheumatic Diseases 2005 64 8 1199 1204 2-s2.0-23444461155 10.1136/ard.2004.029389
26. Machold K. P., Stamm T. A., Nell V. P. K., Pflugbeil S., Aletaha D., Steiner G., Uffmann M., Smolen J. S., Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 2007 46 2 342 349 2-s2.0-33846691023 10.1093/rheumatology/kel237
27. de Vries-Bouwstra J. K., Goekoop-Ruiterman Y. P. M., Verpoort K. N., Schreuder G. M. T., Ewals J. A. P. M., Terwiel J. P., Ronday H. K., Kerstens P. J. S. M., Toes R. E. M., De Vries R. R. P., Breedveld F. C., Dijkmans B. A. C., Huizinga T. W. J., Allaart C. F., Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis and Rheumatism 2008 58 5 1293 1298 2-s2.0-43949096193 10.1002/art.23439
28. Syversen S. W., Goll G. L., van der Heijde D., Landewé R., Lie B. A., Ødegård S., Uhlig T., Gaarder P. I., Kvien T. K., Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Annals of the Rheumatic Diseases 2010 69 2 345 351 2-s2.0-75749090835 10.1136/ard.2009.113092
29. Mathsson L., Mullazehi M., Wick M. C., Sjöberg O., van Vollenhoven R., Klareskog L., Rönnelid J., Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis and Rheumatism 2008 58 1 36 45 2-s2.0-38149026334 10.1002/art.23188
30. Kuhn K. A., Kulik L., Tomooka B., Braschler K. J., Arend W. P., Robinson W. H., Holers V. M., Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. The Journal of Clinical Investigation 2006 116 4 961 973 2-s2.0-33645511657 10.1172/JCI25422
31. Cui J., Taylor K. E., Destefano A. L., Criswell L. A., Izmailova E. S., Parker A., Roubenoff R., Plenge R. M., Weinblatt M. E., Shadick N. A., Karlson E. W., Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis. Molecular Medicine 2009 15 5-6 136 143 2-s2.0-66449088323 10.2119/molmed.2009. 00008
32. Fujikawa K., Kawakami A., Tamai M., Uetani M., Takao S., Arima K., Iwamoto N., Aramaki T., Kawashiri S., Ichinose K., Kamachi M., Nakamura H., Origuchi T., Ida H., Aoyagi K., Eguchi K., High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. Journal of Rheumatology 2009 36 6 1126 1129 2-s2.0-67149101462 10.3899/jrheum.080926
33. Bang H., Lüthke K., Gauliard A., Mutated citrullinated vimentin as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 supplement 2 144
34. Nicaise Roland P., Grootenboer Mignot S., Bruns A., Hurtado M., Palazzo E., Hayem G., Dieudé P., Meyer O., Chollet Martin S., Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Research & Therapy 2008 10 6, article R142 2-s2.0-67949091264
35. Mansour H. E., Metwaly K. M., Hassan I. A., Elshamy H.-A. A., Elbeblawy M. M. S., Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2010 3 33 42 2-s2.0-77955378365
36. Aggarwal R., Liao K., Nair R., Ringold S., Costenbader K. H., Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis and Rheumatism 2009 61 11 1472 1483 2-s2.0-70449515426 10.1002/art.24827